1 / 7

Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC

Phase 2. Treatment Naïve . Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC. Kowdley K, et al. Lancet. 2013;381:2100- 7 . Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Trial : Study Overview.

buffy
Download Presentation

Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 TreatmentNaïve Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6ATOMIC Kowdley K, et al. Lancet. 2013;381:2100-7.

  2. Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6ATOMIC Trial: Study Overview Source: Kowdley K, et al. Lancet. 2013;381:2100-7.

  3. Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6ATOMIC Trial: Design 0 12 24 36 48 Week Cohort An =52 GT 1GT4GT5GT6 SOF +PEG + RBV SVR24 SOF + PEG + RBV Cohort Bn =125 SVR24 Cohort Cn =155 SOF +PEG + RBV SOF SVR24 SOF + RBV Drug DosingSofosbuvir (SOF): 400 mg once dailyRibavirin (RBV) weight-based and divided bid: 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kgPeginterferon alfa-2a (PEG): 180 µg once weekly N =14 Source: Kowdley K, et al. Lancet. 2013;381:2100-7.

  4. Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6ATOMIC Trial: Results, by Cohort (Regimen) ATOMIC: SVR 24 by Cohort (Regimen) 46/52 97/109 135/155 Patients with Genotype 1, 4, or 6 Source: Kowdley K, et al. Lancet. 2013;381:2100-7.

  5. Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6ATOMIC Trial: Results, by Cohort (Regimen) ATOMIC: SVR 24 by Genotype 264/300 9/11 5/5 Notes: (1) No patients with GT5 enrolled in study(2) All patients with GT 4 or 6 received 24 weeks of SOF + PEG + RBV(3) The 2 patients with GT4 and failure resulted from lost to follow-up at end of treatment Source: Kowdley K, et al. Lancet. 2013;381:2100-7.

  6. Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6ATOMIC Trial: Interpretation Source: Kowdley K, et al. Lancet. 2013;381:2100-7.

  7. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related